HK Stock Market Move | YOFC (06869) rose more than 6% at the end of trading, accelerating the evolution of the fiber optic industry. The company is expanding the application of new types of fiber optic products.
Changfei Optical Fiber Cable (06869) closed up more than 6% at the end of the session, with an increase of 5.63% to HK$57.2 at the time of publication, with a trading volume of HK$2.457 billion.
YOFC (06869) rose over 6% at the close, up 5.63% as of the time of writing, at 57.2 Hong Kong dollars, with a turnover of 2.457 billion Hong Kong dollars.
On the news front, it was reported recently that the Lumenisity research team, supported by Microsoft, announced that their newly developed hollow-core optical fiber has achieved the lowest signal attenuation level in history. This achievement was published in the prestigious international journal Nature Photonics on September 1st, marking a significant breakthrough in optical communication technology. It is reported that with the increasing demand for interconnection of data centers driven by AI, the optical fiber industry is accelerating its evolution, with Microsoft and major companies both domestically and internationally speeding up their deployment of hollow-core optical fibers.
Public information shows that in June of this year, China Mobile Limited conducted centralized procurement of G.654.E optical cable products, with a total purchase volume of 3.1386 million fiber kilometers. Yangtze Optical Fibre And Cable Joint Stock won a 50% share in this centralized procurement. At the same time, as the scale of data center clusters increases, the internal optical fiber cable products used for effective transmission distance, latency, and other performance requirements have significantly increased. Changfei's high-end multimode optical fiber, as well as the company's subsidiary, EverProX Technologies, which applies MPO jumpers and AOC and other optical interconnect components to the data center market, have all shown performance growth.
Related Articles
.png)
WING CHI HLDGS (06080) completed the placement of 186.6 million shares of placement shares.

YZYBIO-B(02496): Wang Tao is elected as a staff representative supervisor.

Jiangsu Hengrui Pharmaceuticals(600276.SH): SHR-1139 Injection Receives Approval for Clinical Trials of Drugs
WING CHI HLDGS (06080) completed the placement of 186.6 million shares of placement shares.
.png)
YZYBIO-B(02496): Wang Tao is elected as a staff representative supervisor.

Jiangsu Hengrui Pharmaceuticals(600276.SH): SHR-1139 Injection Receives Approval for Clinical Trials of Drugs
